Aussies OK Aspen's buyout of Sigma; Sanofi, BMS win NICE Plavix expansion;

@FiercePharma: J&J promotes drugs, devices chiefs to vice chair. Report | Follow @FiercePharma

> Australia's competition watchdog cleared Sigma Pharmaceuticals' A$900 million ($887 million) sale of its generic drugs business to South Africa's Aspen Pharmacare after Aspen agreed to give up some products. News

> Sanofi-Aventis and Bristol-Myers Squibb's Plavix blood-thinner won broader indication for use on the U.K.'s National Health Service as the cost-effectiveness watchdog cleared it for people who have had a stroke, peripheral artery disease or multivascular disease. Article

> Cash-strapped states are cutting back on a program that provides free medicine to people with HIV, leaving thousands of patients to wonder where their drugs will come from. Item

> U.K. drugmaker Aesica will double its production capacity with the acquisition of three European manufacturing sites operated by UCB. Report

> The FDA warned makers and distributors of dietary supplements that it is coming after hundreds of products that contain drugs, or compounds acting as drugs. Report

> With a loose web of conservative plaintiffs leading the charge, and judicial rulings breaking thus far along ideological lines, the drive to scuttle the Obama health care law is once again highlighting the role of partisanship in America's courts. Story

> Otsuka shares fell in their second day of trading on the Tokyo Stock Exchange, dropping below the price set by the Japanese drugmaker in the world's largest health-stock initial offering since at least 2006. News

Biotech News

@FierceBiotech: Want the next blockbuster drug? It's all in the delivery. Report | Follow @FierceBiotech 

 @JohnCFierce: Playing catch-up, the FDA issues guidelines on developing new combo drugs. Report | Follow @JohnCFierce

> EMA chief blasts $60B in wasted R&D spending each year. Report

Vaccines News

> FDA lifts hold on Novavax trial. Story

> Single therapeutic vaccine has potential to fight multiple conditions. Report

> Replica vaccine offers new strategy in fight against polio. News

> Merck joins PATH on next-gen malaria vax program. Story

Manufacturing News

> Pfizer compresses as J&J expands ops structure. Story

> U.S. pulls out all the stops to fight counterfeits. Report 

> Feds, sheriff break fake Valium chain. News

> FDA reveals plans for upcoming guidance. Report 

> Airgas warning cites sketchy batch records. Article

> Unichem to apply authentication codes to two drugs. Story

And Finally... With GlaxoSmithKline working on a malaria vaccine, public health officials are debating whether it would be cost-effective in the fight to eliminate the disease. Report

Suggested Articles

New real-world data from Lilly and BI show their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization.

Following its headline-grabbing presentation at ESC, AZ is out with more data that support Farxiga use in nondiabetic heart failure patients.

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.